SciELO - Scientific Electronic Library Online

vol.3 issue1Características del síndrome metabólico en la consulta cardiológica: Grupo de estudio CARISMA (Caracterización y Análisis del Riesgo en Individuos con Síndrome Metabólico en la Argentina)Brain natriuretic peptide in heart failure patients or risk factors to heart failure author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO


Insuficiencia cardíaca

On-line version ISSN 1852-3862


ECHAZARRETA, Diego F. et al. Chronic treatment with PDE-5 inhibitors in patients with advanced heart failure. Insuf. card. [online]. 2008, vol.3, n.1, pp.16-20. ISSN 1852-3862.

Introduction. The persistent increase of pulmonary vascular resistances (PVR) in patients with advanced heart failure (AHF) is the result of pulmonary vascular endothelium dysfunction and its structural remodelling. Diminish of nitride oxide (NO) offer, and the increase of endothelins (ET) strengthen vasoconstrictors phenomenon altering the present equilibrium with the vasodilation mediators. Sildenafil (a selective inhibitor of phosphodiesterasa 5 -PDE5-) may turn into a valid way of increasing NO levels and favouring PVR decrease in patients with AHF. Material and methods. 30 patients with AHF where selected, and divided in two groups of 15 each (sildenafil and control group) with left ventricular ejection fraction (LVEF) of 31.08±3.1% in functional class (FC) III, undergoing complete pharmacological treatment, and being evaluated with 2D transtoracic echocardiogram-colour-Doppler (TCCD) in order to measure the systolic pulmonary arterial pressure (SPAP), with the 6-minute walk test (6MWT) and an ergometric test with maximal oxygen consumption (VO2) at the baseline and at the 90th day of the follow-up. Within this period the sildenafil group received an oral mean dose of the drug of 75.4±13 mg/day. Results. An improvement was shown in the sildenafil group for both functional tests: 6MWT (sildenafil group: day 0: 144.2±42.1 m vs day 90: 171.5±56.8 m p: 0.052) and in ergometric test with VO2 (sildenafil group: day 0: 11.4±1.3ml/Kg/minuto vs day 90: 12.3±1.4 ml/kg/minute; p: 0.001). A decrease in the SPAP was also seen (sildenafil group: day 0: 36.2±6.9 mm Hg vs day 90: 33.8±6.1 mm Hg; p: 0.001); also in the arterial systolic pressure -SAP- (sildenafil group: day 0: 124.6±13.2 mm Hg vs day 90: 116.2±9.5 mm Hg; p: 0.008); and in the diastolic arterial pressure -DAP- (sildenafil group: day 0: 70.8±4.9 mm Hg vs day 90: 65.3±4.3 mm Hg; p: 0.000). Conclusions. The present study shows that the administration of a mean 75.4±13 mg/day oral dose of sildenafil is safe and improves significantly the functional performance of patients with AHF.

Keywords : Heart failure; Pulmonary hypertension; Sildenafil; Phosphodiesterasa 5.

        · abstract in Spanish | Portuguese     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License